Royalty Pharma Acquires Royalty Interest in Alnylam's AMVUTTRA for $310 Million from Blackstone Life Sciences

Royalty Pharma has acquired a royalty interest in Alnylam's AMVUTTRA from Blackstone Life Sciences for $310 million. The royalty interest stems from Blackstone's 2020 financing collaboration with Alnylam. AMVUTTRA is an FDA-approved RNAi therapeutic for the treatment of ATTR amyloidosis, with sales reaching approximately $1 billion in 2024 and projected to exceed $6 billion by 2028. The transaction is expected to deliver returns consistent with Royalty Pharma's stated targets for approved products.